

## **Product** Data Sheet

## LXRβ agonist-3

 Cat. No.:
 HY-146275

 CAS No.:
 2413308-63-9

 Molecular Formula:
 C<sub>30</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S

Molecular Weight: 563.66

Target: LXR

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	LXR $\beta$ agonist-3 (compound 4-13) is a potent and selective LXR $\beta$ (liver X receptor $\beta$ ) agonist, with an EC <sub>50</sub> of 0.095 $\mu$ M. LXR $\beta$ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC <sub>50</sub> of 3.75 $\mu$ M. LXR $\beta$ agonist-3 shows antitumor activity, and can inhibit glioblastoma <sup>[1]</sup> .
IC <sub>50</sub> & Target	$EC_{50}$ : $0.095 \pm 0.012~\mu$ M (LXR $\beta$ ) $0.277 \pm 0.066~\mu$ M (LXR $\alpha$ ) $^{[1]}$
In Vivo	LXRβ agonist-3 (compound 4-13) (BALB/c mice, 50 mg/kg, IP, daily for 15 days) significantly reduces glioblastoma tumor growth <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Chen H, Chen Z, Zhang Z, Li Y, Zhang S, Jiang F, Wei J, Ding P, Zhou H, Gu Q, Xu J. Discovery of new LXRβ agonists as glioblastoma inhibitors. Eur J Med Chem. 2020 May 15;194:112240.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA